Want to see ENVB full AI Analyst Report?
Enveric Biosciences (ENVB) AI Stock Analysis
Enveric Biosciences
(NASDAQ:ENVB)
ENVB scores low primarily due to its fragile financial profile: no revenue, ongoing losses, continuous cash burn, a rapidly shrinking asset base and reliance on dilutive equity issuance to fund operations. Technicals reinforce the caution, with the stock trading well below all major moving averages after a sharp multi-month decline and momentum indicators still weak. Valuation provides no anchor given negative earnings and no dividend. Modest positives — a debt-free balance sheet, a narrowing loss trend, and improved governance and incentive alignment from the recent annual meeting — temper but do not offset the high-risk, speculative nature of this pre-revenue biotech, where the investment case depends entirely on clinical pipeline progress.
Enveric Biosciences (ENVB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 85.46K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- 87.05%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Enveric Biosciences Business Overview & Revenue Model
Company Description
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101...
Enveric Biosciences Financial Statement Overview
Summary
Financials are very weak. Enveric is pre-revenue with zero sales in every reported period and persistent net losses (~$12.1M in 2025, ~$8.7M TTM). Cash flow is deeply negative (operating cash flow of -$8.6M TTM), and the asset base has shrunk from ~$26.7M in 2021 to ~$5.1M in 2025, leaving the company dependent on repeated equity raises and exposing shareholders to dilution and going-concern risk. Partial offsets are a debt-free balance sheet (0.0 debt-to-equity), a narrowing loss trend, and a modest equity rebound to ~$8.1M TTM, but returns on equity remain deeply negative.
Income Statement
8Very NegativeBalance Sheet
25NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -153.92K | -200.86K | -337.49K | -408.03K | -435.20K | -681.61K |
| EBITDA | -8.57M | -8.57M | -9.23M | -16.85M | -19.52M | -55.74M |
| Net Income | -8.73M | -12.13M | -9.57M | ― | -18.50M | -48.98M |
Balance Sheet | ||||||
| Total Assets | 8.94M | 5.10M | 3.08M | 4.30M | 19.55M | 26.72M |
| Cash, Cash Equivalents and Short-Term Investments | 8.30M | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M |
| Total Debt | 0 | 0 | 0 | 0 | 63.82K | 176.30K |
| Total Liabilities | 861.48K | 918.40K | 1.49M | 2.34M | 4.00M | 4.41M |
| Stockholders Equity | 8.08M | 4.18M | 1.59M | 1.96M | 14.67M | 22.31M |
Cash Flow | ||||||
| Free Cash Flow | -8.56M | -8.14M | -7.73M | -14.10M | -17.73M | -12.32M |
| Operating Cash Flow | -8.56M | -8.14M | -7.73M | -14.09M | -17.15M | -11.46M |
| Investing Cash Flow | 0 | 0 | 0 | 11.67K | -584.16K | 2.19M |
| Financing Cash Flow | 14.03M | 10.58M | 7.67M | -1.34M | 18.18M | 24.90M |
Enveric Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Negative. The current price of 1.43 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.45, and below the 200-day MA of 2.02, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 53.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENVB.
Enveric Biosciences Risk Analysis
Enveric Biosciences disclosed 79 risk factors in its most recent earnings report. Enveric Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskEnveric Biosciences Peers Comparison
Overall Rating
INDP51Neutral
BDRX44Neutral
GTBP42Neutral
ARTL40Underperform- ENVB26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INDP | 51Neutral | $474.57M | -0.44 | -302.75% | ― | ― | 81.43% |
| BDRX | 44Neutral | $1.80M | -64.03 | -42.42% | ― | ― | 97.97% |
| GTBP | 42Neutral | $10.96M | -0.05 | -443.08% | ― | ― | 75.09% |
| ARTL | 40Underperform | $1.22M | -0.03 | -519.09% | ― | ― | 59.79% |
| ENVB | 26Underperform | $6.40M | -0.09 | -168.05% | ― | ― | 87.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | 1.43 | -5.65 | -79.80% | |
| BDRX | Biodexa Pharmaceuticals Plc | 3.43 | -243.77 | -98.61% | |
| INDP | Indaptus Therapeutics, Inc. | 3.09 | -0.03 | -0.96% | |
| GTBP | Gt Biopharma, Inc. | 5.32 | -10.26 | -65.85% | |
| ARTL | Artelo Biosciences | 2.22 | -78.78 | -97.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026